0000000001019806

AUTHOR

C. Contini

showing 4 related works from this author

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

2014

a b s t r a c t Background: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in “real world” chronic hepatitis C patients in Italy. Methods: Independent observational multicentre study including consecutive patients receiving Peginterferon/ribavirin in the 18 months before (retrospective phase) and after (prospective phase) the start of the study. Results: 4176 patients were eligible. The final study population consisted of 2051 patients in the retrospective and 2073 in the prospective phase. Sust…

RegistrieMaleCirrhosismedicine.disease_causePolyethylene GlycolGastroenterologyPolyethylene Glycolschemistry.chemical_compoundHepatitis VirusesHepatitis ViruseProspective StudiesViralRegistriesChronicProspective cohort studyDrug CarrierDrug CarriersSettore MED/12 - GastroenterologiaMedicine (all)GastroenterologyRecombinant ProteinMiddle AgedHepatitis CRecombinant ProteinsTreatment OutcomeItalyCombinationRNA ViralPopulation studyDrug Therapy CombinationFemaleHumanmedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonRibavirin; Sustained virological response (SVR); TreatmentAntiviral AgentsFollow-Up StudieRibavirin; Sustained virological response (SVR); Treatment; Hepatology; GastroenterologyDrug TherapyInternal medicineRibavirinmedicineHumansAntiviral AgentHepatologybusiness.industryRibavirinInterferon-alphaHCV therapyHepatitis C ChronicHepatologymedicine.diseaseClinical trialTreatmentProspective StudiechemistryImmunologyRNARibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; RegistriesbusinessRibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; Registries; Gastroenterology; Hepatology; Medicine (all)Follow-Up StudiesSustained virological response (SVR)
researchProduct

Use of Calprest ® in the diagnosis of Inflammatory Bowel Disease (IBD)

2002

Abstract Background: Between November 2000 and February 2001 a study has been performed by eight Italian hospital centers with the aim of verifying the usefulness of Calprest® (detection of fecal calprotectin) as a marker of bowel inflammation. Preliminary data are reported. Objective: To define the use of fecal calprotectin as a marker of intestinal inflammation, to assess whether it might help in differentiating between IBS and IBD, and its role in IBD. Subjects: Healthy population (51), active Crohn (16), non active or under remission Crohn (11), active ulcerative Colitis (8), non active or under remission ulcerative Colitis (13), pathological Controls of various nature (79). Results: Th…

medicine.medical_specialtybusiness.industryImmunologyInflammationmedicine.diseaseNegative Test ResultMicrobiologyGastroenterologyInflammatory bowel diseaseUlcerative colitisdigestive system diseasesInfectious DiseasesIntestinal inflammationInternal medicineImmunologyImmunology and AllergyMedicineCalprotectinmedicine.symptombusinessPathologicalFecesClinical and Applied Immunology Reviews
researchProduct

The THESEUS space mission concept: science case, design and expected performances

2018

THESEUS is a space mission concept aimed at exploiting Gamma-Ray Bursts for investigating the early Universe and at providing a substantial advancement of multi-messenger and time-domain astrophysics. These goals will be achieved through a unique combination of instruments allowing GRB and X-ray transient detection over a broad field of view (more than 1sr) with 0.5¿1 arcmin localization, an energy band extending from several MeV down to 0.3¿keV and high sensitivity to transient sources in the soft X-ray domain, as well as on-board prompt (few minutes) follow-up with a 0.7¿m class IR telescope with both imaging and spectroscopic capabilities. THESEUS will be perfectly suited for addressing …

IonizationAtmospheric Sciencecosmological modelCherenkov Telescope Array[ PHYS.ASTR ] Physics [physics]/Astrophysics [astro-ph]AstronomyDark ageMASSIVE SINGLE STARSStar formation rates Gamma ray01 natural sciencesCosmology: observationlocalizationlaw.inventionAstrophysicEinstein Telescopeobservational cosmologylawObservational cosmologyRe-ionizationCosmology: observations; Dark ages; First stars; Gamma-ray: bursts; Re-ionizationLIGOobservations [Cosmology]Telescope010303 astronomy & astrophysicsHigh sensitivityHigh Energy Astrophysical Phenomena (astro-ph.HE)PhysicsMulti-wavelengthenergy: highsezelegamma-ray burstsCosmology: observationsCosmology: observations; Dark ages; First stars; Gamma-ray: bursts; Re-ionization; Aerospace Engineering; Space and Planetary ScienceAstrophysics::Instrumentation and Methods for Astrophysicsimagingstar: formationburst [Gamma-ray]observatoryGeophysicsDark agesX rays Cosmology: observationAstrophysics - Instrumentation and Methods for AstrophysicsAstrophysics - High Energy Astrophysical PhenomenasignatureStarTIDAL DISRUPTIONGamma-ray: burstAstrophysics::High Energy Astrophysical PhenomenaSIMILAR-TO 6Socio-culturaleFOS: Physical sciencesAerospace EngineeringGamma-ray: burstsobservation [Cosmology]galaxy: luminosityX-ray astronomy: instrumentation7 CANDIDATE GALAXIESAstrophysics::Cosmology and Extragalactic Astrophysicsgamma ray: burst114 Physical sciencesSettore FIS/03 - Fisica della MateriaTelescopeX-raybursts [Gamma-ray]FIS/05 - ASTRONOMIA E ASTROFISICASettore FIS/05 - Astronomia e AstrofisicaFirst star0103 physical sciences[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]KAGRAInstrumentation and Methods for Astrophysics (astro-ph.IM)Astrophysics::Galaxy AstrophysicsFirst starsLIGHT CURVESEinstein Telescope010308 nuclear & particles physicsGravitational wavegravitational radiationAstronomyAstronomy and Astrophysics115 Astronomy Space scienceCherenkov Telescope ArrayredshiftsensitivityRedshiftNEUTRON-STAR MERGERmessengerVIRGOelectromagneticLUMINOSITY FUNCTIONSpace and Planetary ScienceBLACK-HOLEGeneral Earth and Planetary SciencesGamma-ray burst[PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph]
researchProduct

Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry

2018

Skin and soft tissue infections (SSTIs) represent a wide range of clinical conditions characterized by a considerable variety of clinical presentations and severity. Their aetiology can also vary, with numerous possible causative pathogens. While other authors previously published analyses on several types of SSTI and on restricted types of patients, we conducted a large nationwide surveillance programme on behalf of the Italian Society of Infectious and Tropical Diseases to assess the clinical and microbiological characteristics of the whole SSTI spectrum, from mild to severe life-threatening infections, in both inpatients and outpatients. Twenty-five Infectious Diseases (ID) Centres throu…

0301 basic medicineAdultMalemedicine.medical_specialtyAdolescentEpidemiology030106 microbiologySocio-culturaleregistryEpidemiology; microbiology; registry; skin and soft tissue infections; Oncology; Pharmacology; Pharmacology (medical); Infectious Diseases03 medical and health sciencesEpidemiology microbiology skin and soft tissue infections registryYoung Adult0302 clinical medicineskin and soft tissue infectionEpidemiologymedicineHumansPharmacology (medical)RegistriesSkin Diseases InfectiousAgedAged 80 and overPharmacologybusiness.industrySoft Tissue Infectionsmicrobiologyfood and beveragesSoft tissueMiddle AgedDermatologyskin and soft tissue infectionsInfectious DiseasesItalyOncology030220 oncology & carcinogenesisEtiologyFemaleNational registrybusiness
researchProduct